Interleukin-21 in autoimmune and inflammatory skin diseases.
Autoimmunity
Signal transduction
Skin diseases/immunology
T cells
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
01
02
2023
received:
30
06
2022
accepted:
20
02
2023
medline:
12
4
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Studies on the role of interleukins (ILs) in autoimmune and inflammatory diseases allow for the better understanding of pathologic mechanisms of disease and reshaping of treatment modalities. The development of monoclonal antibodies targeting specific ILs or IL signaling pathways (i.e., anti-IL-17/IL-23 in psoriasis or anti-IL-4/IL-13 in atopic dermatitis) is the shining example of therapeutic interventions in research. IL-21, belonging to the group of ɣc-cytokines (IL-2, IL-4, IL-7, IL-9, and IL-15), is gaining attention for its pleiotropic role in several types of immune cells as activator of various inflammatory pathways. In both health and disease, IL-21 sustains T- and B-cell activity. Together with IL-6, IL-21 helps to generate Th17 cells, promotes CXCR5 expression in T cells, and their maturation into follicular T helper cells. In B cells, IL-21 sustains their proliferation and maturation into plasma cells and promotes class switching and antigen-specific antibody production. Due to these characteristics, IL-21 is a main factor in numerous immunologic disorders, such as rheumatoid arthritis and MS. Studies in preclinical skin disease models and on human skin strongly suggest that IL-21 is crucially involved in inflammatory and autoimmune cutaneous disorders. Here, we summarize the current knowledge of IL-21 in well-known skin diseases.
Identifiants
pubmed: 36811452
doi: 10.1002/eji.202250075
doi:
Substances chimiques
interleukin-21
MKM3CA6LT1
Interleukins
0
Cytokines
0
Interleukin-13
0
Interleukin-23
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2250075Informations de copyright
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Isaacs, A., Lindenmann, J. and Andrewes, C.H., Virus interference. I. The interferon. Proc. R. Soc. Lond. Ser. B - Biol. Sci. 1957. 147: 258-267.
Eyerich, K. and Eyerich, S., Immune response patterns in non-communicable inflammatory skin diseases. J. Eur. Acad. Dermatol. Venereol. 2018. 32: 692-703.
Solimani, F., Meier, K. and Ghoreschi, K., Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019. 10: 2847.
Yazdi, A. S., Rocken, M. and Ghoreschi, K., Cutaneous immunology: basics and new concepts. Semin. Immunopathol. 2016. 38: 3-10.
Solimani, F., Hilke, F. J. and Ghoreschi, K., [Pharmacology of Janus kinase inhibitors]. Hautarzt 2019. 70: 934-941.
Bieber, T., Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy 2020. 75: 54-62.
Ghoreschi, K., Balato, A., Enerback, C. and Sabat, R., Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 2021. 397: 754-766.
Crotty, S., Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 2011. 29: 621-663.
Victora, G. D. and Nussenzweig, M. C., Germinal centers. Annu. Rev. Immunol. 2012. 30: 429-457.
Vinuesa, C. G., Linterman, M. A., Yu, D. and MacLennan, I. C., Follicular helper T cells. Annu. Rev. Immunol. 2016. 34: 335-368.
Parrish-Novak, J., Dillon, S. R., Nelson, A., Hammond, A., Sprecher, C., Gross, J. A., Johnston, J. et al., Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000. 408: 57-63.
Spolski, R. and Leonard, W. J., Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 2008. 26: 57-79.
Kasaian, M. T., Whitters, M. J., Carter, L. L., Lowe, L. D., Jussif, J. M., Deng, B., Johnson, K. A. et al., IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002;16: 559-569.
Ozaki, K., Kikly, K., Michalovich, D., Young, P. R. and Leonard, W. J., Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc. Natl. Acad. Sci. U S A. 2000. 97: 11439-11444.
Ozaki, K., Spolski, R., Ettinger, R., Kim, H. P., Wang, G., Qi, C. F., Hwu, P. et al., Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 2004. 173: 5361-5371.
Ozaki, K., Spolski, R., Feng, C. G., Qi, C. F., Cheng, J., Sher, A., Morse, H. C. et al., A critical role for IL-21 in regulating immunoglobulin production. Science 2002. 298: 1630-1634.
Kotlarz, D., Zietara, N., Milner, J. D. and Klein, C., Human IL-21 and IL-21R deficiencies: two novel entities of primary immunodeficiency. Curr. Opin. Pediatr. 2014. 26: 704-712.
Salzer, E., Kansu, A., Sic, H., Majek, P., Ikinciogullari, A., Dogu, F. E., Prengemann, N. et al., Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J. Allergy Clin. Immunol. 2014. 133: 1651-1659.e12.
Kotlarz, D., Zietara, N., Uzel, G., Weidemann, T., Braun, C. J., Diestelhorst, J., Krawitz, P. M. et al., Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J. Exp. Med. 2013. 210: 433-443.
Leonard, W. J., Lin, J. X. and O'Shea, J. J., The γ(c) family of cytokines: basic biology to therapeutic ramifications. Immunity 2019. 50: 832-850.
Asao, H., Okuyama, C., Kumaki, S., Ishii, N., Tsuchiya, S., Foster, D., Sugamura, K. et al., Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 2001. 167: 1-5.
Noguchi, M., Yi, H., Rosenblatt, H. M., Filipovich, A. H., Adelstein, S., Modi, W. S. et al., Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993. 73: 147-157.
Pesu, M., Candotti, F., Husa, M., Hofmann, S. R., Notarangelo, L. D. and O'Shea, J. J., Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol. Rev. 2005. 203: 127-142.
Ghoreschi, K., Laurence, A. and O'Shea, J. J., Janus kinases in immune cell signaling. Immunol. Rev. 2009. 228: 273-287.
Caruso, R., Fina, D., Peluso, I., Stolfi, C., Fantini, M. C., Gioia, V., Caprioli, F. et al., A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007. 132: 166-175.
Guan, L. J., Wang, X., Meng, S., Shi, L. F., Jiang, W. J., Xiao, L., Shi, X. et al., Increased IL-21/IL-21R expression and its proinflammatory effects in autoimmune thyroid disease. Cytokine 2015. 72: 160-165.
Zhang, J., Ren, M., Zeng, H., Guo, Y., Zhuang, Z., Feng, Z., Yan, H. et al., Elevated follicular helper T cells and expression of IL-21 in thyroid tissues are involved in the pathogenesis of Graves' disease. Immunol. Res. 2015. 62: 163-174.
Jüngel, A., Distler, J. H., Kurowska-Stolarska, M., Seemayer, C. A., Seibl, R., Forster, A., Michel, B. A. et al., Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum. 2004. 50: 1468-1476.
Xing, R., Yang, L., Jin, Y., Sun, L., Li, C., Li, Z., Zhao, J. et al., Interleukin-21 induces proliferation and proinflammatory cytokine profile of fibroblast-like synoviocytes of patients with rheumatoid arthritis. Scand. J. Immunol. 2016. 83: 64-71.
Wang, T., Cunningham, A., Houston, K., Sharma, A. M., Chen, L., Dokun, A. O., Lye, R. J.et al., Endothelial interleukin-21 receptor up-regulation in peripheral artery disease. Vasc. Med. 2016. 21: 99-104.
Xu, D., Chen, P., Xiao, H., Wang, X., DiSanto, M. E. and Zhang, X., Upregulated interleukin 21 receptor enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia. Front. Endocrinol. (Lausanne) 2019. 10: 4.
Distler, J. H., Jüngel, A., Kowal-Bielecka, O., Michel, B. A., Gay, R. E., Sprott, H., Matucci-Cerinic, M. et al., Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 2005. 52: 856-864.
Spolski, R. and Leonard, W. J., Interleukin-21: a double-edged sword with therapeutic potential. Nat. Rev. Drug Discov. 2014. 13: 379-395.
Caprioli, F., Sarra, M., Caruso, R., Stolfi, C., Fina, D., Sica, G., MacDonald, T. T. et al., Autocrine regulation of IL-21 production in human T lymphocytes. J. Immunol. 2008. 180: 1800-1807.
Suto, A., Kashiwakuma, D., Kagami, S., Hirose, K., Watanabe, N., Yokote, K., Saito, Y. et al., Development and characterization of IL-21-producing CD4+ T cells. J. Exp. Med. 2008. 205: 1369-1379.
Biswas, P. S., Gupta, S., Chang, E., Song, L., Stirzaker, R. A., Liao, J. K., Bhagat, G. et al., Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 2010. 120: 3280-3295.
Chen, Q., Yang, W., Gupta, S., Biswas, P., Smith, P., Bhagat, G., Pernis, A. B. et al., IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008. 29: 899-911.
Rozo, C., Chinenov, Y., Maharaj, R. K., Gupta, S., Leuenberger, L., Kirou, K. A., Bykerk, V. P. et al., Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE. Ann. Rheum. Dis. 2017. 76: 740-747.
Kim, H. P., Korn, L. L., Gamero, A. M. and Leonard, W. J., Calcium-dependent activation of interleukin-21 gene expression in T cells. J. Biol. Chem. 2005. 280: 25291-25297.
Hiramatsu, Y., Suto, A., Kashiwakuma, D., Kanari, H., Kagami, S., Ikeda, K., Hirose, K. et al., c-Maf activates the promoter and enhancer of the IL-21 gene, and TGF-beta inhibits c-Maf-induced IL-21 production in CD4+ T cells. J. Leukoc. Biol. 2010. 87: 703-712.
Kroenke, M. A., Eto, D., Locci, M., Cho, M., Davidson, T., Haddad, E. K., Crotty, S. et al., Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J. Immunol. 2012. 188: 3734-3744.
Liu, Y. W., Fu, S. H., Chien, M. W., Hsu, C. Y., Lin, M. H., Dong, J. L., Lu, R. J.-H. et al., Blimp-1 molds the epigenetic architecture of IL-21-mediated autoimmune diseases through an autoregulatory circuit. JCI Insight. 2022. 7: e151614.
Johnston, R. J., Poholek, A. C., DiToro, D., Yusuf, I., Eto, D., Barnett, B., Dent, A. L. et al., Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009. 325: 1006-1010.
Lee, J., Shin, E. K., Lee, S. Y., Her, Y. M., Park, M. K., Kwok, S. K., Ju, J. H. et al., Oestrogen up-regulates interleukin-21 production by CD4(+) T lymphocytes in patients with systemic lupus erythematosus. Immunology 2014. 142: 573-580.
Monteiro, C., Kasahara, T., Sacramento, P. M., Dias, A., Leite, S., Silva, V. G., Gupta. S. et al., Human pregnancy levels of estrogen and progesterone contribute to humoral immunity by activating T(FH) /B cell axis. Eur. J. Immunol. 2021. 51: 167-179.
Korn, T., Bettelli, E., Gao, W., Awasthi, A., Jager, A., Strom, T. B., Oukka, M. et al., IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007. 448: 484-487.
Chen, J., Guan, L., Tang, L., Liu, S., Zhou, Y., Chen, C., He, Z. et al., T helper 9 cells: a new player in immune-related diseases. DNA Cell Biol. 2019. 38: 1040-1047.
Wong, M. T., Ye, J. J., Alonso, M. N., Landrigan, A., Cheung, R. K., Engleman, E., Utz, P. J. et al., Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol. Cell Biol. 2010. 88: 624-631.
Vegran, F., Berger, H., Boidot, R., Mignot, G., Bruchard, M., Dosset, M., Chalmin, F. et al., The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat. Immunol. 2014. 15: 758-766.
Schmitz, I., Schneider, C., Frohlich, A., Frebel, H., Christ, D., Leonard, W. J., Sparwasser, T. et al., IL-21 restricts virus-driven Treg cell expansion in chronic LCMV infection. PLoS Pathog. 2013. 9: e1003362.
Attridge, K., Wang, C. J., Wardzinski, L., Kenefeck, R., Chamberlain, J. L., Manzotti, C., Kopf, M. et al., IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 2012. 119: 4656-4664.
Nurieva, R., Yang, X. O., Martinez, G., Zhang, Y., Panopoulos, A. D., Ma, L., Schluns, K. et al., Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007. 448: 480-483.
Spolski, R., Kim, H. P., Zhu, W., Levy, D. E. and Leonard, W. J., IL-21 mediates suppressive effects via its induction of IL-10. J. Immunol. 2009. 182: 2859-2867.
Pot, C., Jin, H., Awasthi, A., Liu, S. M., Lai, C. Y., Madan, R., Sharpe, A. H. et al., Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 2009. 183: 797-801.
Quast, I., Dvorscek, A. R., Pattaroni, C., Steiner, T. M., McKenzie, C. I., Pitt, C., O'Donnell, K. et al., Interleukin-21, acting beyond the immunological synapse, independently controls T follicular helper and germinal center B cells. Immunity 2022. 55: 1414-1430.e5.
Weinstein, J. S., Herman, E. I., Lainez, B., Licona-Limon, P., Esplugues, E., Flavell, R., Craft, J. et al., TFH cells progressively differentiate to regulate the germinal center response. Nat. Immunol. 2016. 17: 1197-1205.
Luthje, K., Kallies, A., Shimohakamada, Y., Belz, G. T., Light, A., Tarlinton, D. M., Nutt, S. L. et al., The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. Nat. Immunol. 2012. 13: 491-498.
Chung, Y., Tanaka, S., Chu, F., Nurieva, R. I., Martinez, G. J., Rawal, S., Wang, Y. -. H. et al., Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat. Med. 2011. 17: 983-988.
Linterman, M. A., Pierson, W., Lee, S. K., Kallies, A., Kawamoto, S., Rayner, T. F., Srivastava, M. et al., Foxp3+ follicular regulatory T cells control the germinal center response. Nat. Med. 2011. 17: 975-982.
Walker, L. S. K., The link between circulating follicular helper T cells and autoimmunity. Nat. Rev. Immunol. 2022. 22: 567-575.
Sage, P. T., Ron-Harel, N., Juneja, V. R., Sen, D. R., Maleri, S., Sungnak, W., Kuchroo, V. K. et al., Suppression by TFR cells leads to durable and selective inhibition of B cell effector function. Nat. Immunol. 2016. 17: 1436-1446.
Sage, P. T., Alvarez, D., Godec, J., von Andrian, U. H. and Sharpe, A. H., Circulating T follicular regulatory and helper cells have memory-like properties. J. Clin. Invest. 2014. 124: 5191-5204.
Ding, Y., Li, J., Yang, P., Luo, B., Wu, Q., Zajac, A. J., Wildner, O. et al., Interleukin-21 promotes germinal center reaction by skewing the follicular regulatory T cell to follicular helper T cell balance in autoimmune BXD2 mice. Arthritis Rheumatol. 2014. 66: 2601-2612.
Jandl, C., Liu, S. M., Canete, P. F., Warren, J., Hughes, W. E., Vogelzang, A., Webster, K. et al., IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2. Nat. Commun. 2017. 8: 14647.
Wolfarth, A. A., Dhar, S., Goon, J. B., Ezeanya, U. I., Ferrando-Martinez, S. and Lee, B. H., Advancements of common gamma-chain family cytokines in cancer immunotherapy. Immune Netw. 2022. 22: e5.
Moens, L. and Tangye, S. G., Cytokine-mediated regulation of plasma cell generation: IL-21 Takes Center Stage. Front Immunol. 2014. 5: 65.
Suto, A., Nakajima, H., Hirose, K., Suzuki, K., Kagami, S., Seto, Y., Hoshimoto, A. et al., Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood 2002. 100: 4565-4573.
Shang, X. Z., Ma, K. Y., Radewonuk, J., Li, J., Song, X. Y., Griswold, D. E., Emmell, E. et al., IgE isotype switch and IgE production are enhanced in IL-21-deficient but not IFN-gamma-deficient mice in a Th2-biased response. Cell. Immunol. 2006. 241: 66-74.
Haase, P. and Voehringer, D., Regulation of the humoral type 2 immune response against allergens and helminths. Eur. J. Immunol. 2021. 51: 273-279.
Tangye, S. G. and Ma, C. S., Regulation of the germinal center and humoral immunity by interleukin-21. J. Exp. Med. 2020. 217.
Good, K. L., Bryant, V. L. and Tangye, S. G., Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J. Immunol. 2006. 177: 5236-5247.
Deenick, E. K., Avery, D. T., Chan, A., Berglund, L. J., Ives, M. L., Moens, L., Stoddard, J. L et al., Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J. Exp. Med. 2013. 210: 2739-2753.
Avery, D. T., Deenick, E. K., Ma, C. S., Suryani, S., Simpson, N., Chew, G. Y., Chan, T. D. et al., B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 2010. 207: 155-171.
Berglund, L. J., Avery, D. T., Ma, C. S., Moens, L., Deenick, E. K., Bustamante, J., Boisson-Dupuis, S. et al., IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood 2013. 122: 3940-3950.
Dvorscek, A. R., McKenzie, C. I., Robinson, M. J., Ding, Z., Pitt, C., O'Donnell, K., Zotos, D. et al., IL-21 has a critical role in establishing germinal centers by amplifying early B cell proliferation. EMBO Rep. 2022. 23: e54677.
Rodríguez-Bayona, B., Ramos-Amaya, A., Bernal, J., Campos-Caro, A. and Brieva, J. A., Cutting edge: IL-21 derived from human follicular helper T cells acts as a survival factor for secondary lymphoid organ, but not for bone marrow, plasma cells. J. Immunol. 2012. 188: 1578-1581.
Ettinger, R., Sims, G. P., Fairhurst, A. M., Robbins, R., da Silva, Y. S., Spolski, R., Leonard, W. J. et al., IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 2005. 175: 7867-7879.
Mehta, D. S., Wurster, A. L., Whitters, M. J., Young, D. A., Collins, M., Grusby, M. J., IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 2003. 170: 4111-4118.
Jin, H., Carrio, R., Yu, A. and Malek, T. R., Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 2004. 173: 657-665.
de Bruin-Weller, M. S., Serra-Baldrich, E., Barbarot, S., Grond, S., Schuster, C., Petto, H., Capron, J. -. P. et al., Indirect treatment comparison of baricitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis. Dermatol. Ther. (Heidelb) 2022. 12: 1481-1491.
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K. and Irvine, A. D., Atopic dermatitis. Nat. Rev. Dis. Primers 2018. 4: 1.
Kraft, M. and Worm, M., Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev. Clin. Immunol. 2017. 13: 301-310.
Worm, M., Francuzik, W., Kraft, M. and Alexiou, A., Modern therapies in atopic dermatitis: biologics and small molecule drugs. J. Dtsch. Dermatol. Ges. 2020. 18: 1085-1092.
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R. et al., Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J. Allergy Clin. Immunol. 2019. 143: 135-141.
Noda, S., Suarez-Farinas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X. et al., The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J. Allergy Clin. Immunol. 2015. 136: 1254-1264.
Brunner, P. M. and Guttman-Yassky, E., Racial differences in atopic dermatitis. Ann. Allergy Asthma Immunol. 2019. 122: 449-455.
Roesner, L. M. and Werfel, T., Autoimmunity (or not) in atopic dermatitis. Front Immunol. 2019. 10: 2128.
Novak, N., An update on the role of human dendritic cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2012. 129: 879-886.
Jin, H., Oyoshi, M. K., Le, Y., Bianchi, T., Koduru, S., Mathias, C. B., Kumar, L. et al., IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J. Clin. Invest. 2009. 119: 47-60.
Mizutani, H., Tamagawa-Mineoka, R., Nakamura, N., Masuda, K. and Katoh, N., Serum IL-21 levels are elevated in atopic dermatitis patients with acute skin lesions. Allergol. Int. 2017. 66: 440-444.
Szabo, K., Gaspar, K., Dajnoki, Z., Papp, G., Fabos, B., Szegedi, A., Zeher, M. et al., Expansion of circulating follicular T helper cells associates with disease severity in childhood atopic dermatitis. Immunol. Lett. 2017. 189: 101-108.
Czarnowicki, T., Kim, H. J., Villani, A. P., Glickman, J., Duca, E. D., Han, J., Pavel, A. B. et al., High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitis. Allergy 2021. 76: 3080-3093.
Yang, Z., Wu, C. M., Targ, S. and Allen, C. D. C., IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells. J. Exp. Med. 2020. 217: e20190472.
Blauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H. et al., Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021. 157: 1047.
Le Cleach, L. and Chosidow, O., Clinical practice. Lichen planus. N. Engl. J. Med. 2012. 366: 723-732.
Boch, K., Langan, E. A., Zillikens, D., Ludwig, R. J. and Kridin, K., Retrospective analysis of the clinical characteristics and patient-reported outcomes in vulval lichen planus: results from a single-center study. J. Dermatol. 2021. 48: 1913-1917.
Shao, S., Tsoi, L. C., Sarkar, M. K., Xing, X., Xue, K., Uppala, R., Berthier, C. C. et al., IFN-gamma enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci. Transl. Med. 2019. 11: eaav7561.
Pietschke, K., Holstein, J., Meier, K., Schafer, I., Muller-Hermelink, E., Gonzalez-Menendez, I., Quintanilla-Martinez, L. et al., The inflammation in cutaneous lichen planus is dominated by IFN-Upsilon and IL-21-A basis for therapeutic JAK1 inhibition. Exp. Dermatol. 2021. 30: 262-270.
Schmidt, T., Solimani, F., Pollmann, R., Stein, R., Schmidt, A., Stulberg, I., Kühn, K. et al., TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. J. Allergy Clin. Immunol. 2018. 142: 669-672.e7.
Del Duca, E., Ruano Ruiz, J., Pavel, A. B., Sanyal, R. D., Song, T., Gay-Mimbrera, J., Zhang, N. et al., Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing. Br. J. Dermatol. 2020. 183: 1083-1093.
Solimani, F., Pollmann, R., Schmidt, T., Schmidt, A., Zheng, X., Savai, R., Mühlenbein, S. et al., Therapeutic targeting of Th17/Tc17 cells leads to clinical improvement of lichen planus. Front. Immunol. 2019. 10: 1808.
Gueiros, L. A., Arao, T., Souza, T., Vieira, C. L., Gomez, R. S., Almeida, O. P., Lodi, G. et al., IL17A polymorphism and elevated IL17A serum levels are associated with oral lichen planus. Oral Dis. 2018. 24: 377-383.
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G. et al., Systemic lupus erythematosus. Nat. Rev. Dis. Primers 2016. 2: 16039.
Tsokos, G. C., Systemic lupus erythematosus. N. Engl. J. Med. 2011. 365: 2110-2121.
Nguyen, V., Luzina, I., Rus, H., Tegla, C., Chen, C. and Rus, V., IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms. J. Immunol. 2012. 189: 1081-1093.
McPhee, C. G., Bubier, J. A., Sproule, T. J., Park, G., Steinbuck, M. P., Schott, W. H., Christianson, G. J et al., IL-21 is a double-edged sword in the systemic lupus erythematosus-like disease of BXSB.Yaa mice. J. Immunol. 2013. 191: 4581-4588.
Nakou, M., Papadimitraki, E. D., Fanouriakis, A., Bertsias, G. K., Choulaki, C., Goulidaki, N., Sidiropoulos, P. et al., Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells. Clin. Exp. Rheumatol. 2013. 31: 172-179.
Shater, H., Fawzy, M., Farid, A., El-Amir, A., Fouad, S. and Madbouly, N., The potential use of serum interleukin-21 as biomarker for lupus nephritis activity compared to cytokines of the tumor necrosis factor (TNF) family. Lupus 2022. 31: 55-64.
Wu, H., Deng, Y., Long, D., Yang, M., Li, Q., Feng, Y., Chen, Y. et al., The IL-21-TET2-AIM2-c-MAF pathway drives the T follicular helper cell response in lupus-like disease. Clin. Transl. Med. 2022. 12: e781.
Bubier, J. A., Bennett, S. M., Sproule, T. J., Lyons, B. L., Olland, S., Young, D. A., Roopenian, D. C. et al., Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann. N.Y. Acad. Sci. 2007. 1110: 590-601.
Herber, D., Brown, T. P., Liang, S., Young, D. A., Collins, M. and Dunussi-Joannopoulos, K., IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J. Immunol. 2007. 178: 3822-3830.
Dolff, S., Abdulahad, W. H., Westra, J., Doornbos-van der Meer, B., Limburg, P. C., Kallenberg, C. G., Bijl, M. et al., Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2011. 13: R157.
Terrier, B., Costedoat-Chalumeau, N., Garrido, M., Geri, G., Rosenzwajg, M., Musset, L., Klatzmann, D. et al., Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J. Rheumatol. 2012. 39: 1819-1828.
Salvi, V., Vermi, W., Cavani, A., Lonardi, S., Carbone, T., Facchetti, F., Bosisio, D. et al., IL-21 may promote granzyme B-dependent NK/plasmacytoid dendritic cell functional interaction in cutaneous lupus erythematosus. J. Invest. Dermatol. 2017. 137: 1493-1500.
Didona, D., Maglie, R., Eming, R. and Hertl, M., Pemphigus: current and future therapeutic strategies. Front. Immunol. 2019. 10: 1418.
Kasperkiewicz, M., Ellebrecht, C. T., Takahashi, H., Yamagami, J., Zillikens, D., Payne, A. S. and Amagai, M., Pemphigus. Nat. Rev. Dis. Primers 2017. 3: 17026.
Amber, K. T., Maglie, R., Solimani, F., Eming, R., Hertl, M., Targeted therapies for autoimmune bullous diseases: current status. Drugs 2018. 78: 1527-1548.
Hertl, M. and Veldman, C., T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun. Rev. 2003. 2: 278-283.
Veldman, C., Stauber, A., Wassmuth, R., Uter, W., Schuler, G. and Hertl, M., Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J. Immunol. 2003. 170: 635-642.
Eming, R., Nagel, A., Wolff-Franke, S., Podstawa, E., Debus, D. and Hertl, M., Rituximab exerts a dual effect in pemphigus vulgaris. J. Invest. Dermatol. 2008. 128: 2850-2858.
Hennerici, T., Pollmann, R., Schmidt, T., Seipelt, M., Tackenberg, B., Mobs, C., Ghoreschi, K. et al., Increased frequency of t follicular helper cells and elevated interleukin-27 plasma levels in patients with pemphigus. PLoS One 2016. 11: e0148919.
Holstein, J., Solimani, F., Baum, C., Meier, K., Pollmann, R., Didona, D., Tekath, T. et al., Immunophenotyping in pemphigus reveals a TH17/TFH17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody production. J. Allergy Clin. Immunol. 2021. 147: 2358-2369.
Yuan, H., Zhou, S., Liu, Z., Cong, W., Fei, X., Zeng, W., Zhu, H. et al., Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis. J. Invest. Dermatol. 2017. 137: 2362-2370.
Zou, Y., Yuan, H., Zhou, S., Zhou, Y., Zheng, J., Zhu, H., Pan, M. et al., The pathogenic role of CD4(+) tissue-resident memory T cells bearing T follicular helper-like phenotype in pemphigus lesions. J. Invest. Dermatol. 2021. 141: 2141-2150.
Kim, A. R., Han, D., Choi, J. Y., Seok, J., Kim, S. E., Seo, S. H., Takahashi, H. et al., Targeting inducible costimulator expressed on CXCR5(+)PD-1(+) TH cells suppresses the progression of pemphigus vulgaris. J. Allergy Clin. Immunol. 2020. 146: 1070-1079.e8.
Maho-Vaillant, M., Perals, C., Golinski, M. L., Hebert, V., Caillot, F., Mignard, C., Riou, G. et al., Rituximab and corticosteroid effect on desmoglein-specific B cells and desmoglein-specific T follicular helper cells in pemphigus. J. Invest. Dermatol. 2021. 141: 2132-2140.e1.
Greb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., Mehta, N. N. et al., Psoriasis. Nat. Rev. Dis. Primers 2016. 2: 16082.
Sabat, R., Wolk, K., Loyal, L.,, Docke, W. D. and Ghoreschi, K. T cell pathology in skin inflammation. Semin. Immunopathol. 2019. 41: 359-377.
Caruso, R., Botti, E., Sarra, M., Esposito, M., Stolfi, C., Diluvio, L., Giustizieri, M. L et al., Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat. Med. 2009. 15: 1013-1015.
Kim, H. J., Kim, S. H., Kim, T. G., Park, J. Y., Lee, M., Kim, D. S., Lee, M.-G. et al., Interleukin-21 receptor signalling is not critically required for imiquimod-induced psoriasiform dermatitis in mice. Exp. Dermatol. 2018. 27: 191-195.
Wang, Y., Wang, L. L., Yang, H. Y., Wang, F. F., Zhang, X. X. and Bai, Y. P., Interleukin-21 is associated with the severity of psoriasis vulgaris through promoting CD4+ T cells to differentiate into Th17 cells. Am. J. Transl. Res. 2016. 8: 3188-3196.
Shi, Y., Chen, Z., Zhao, Z., Yu, Y., Fan, H., Xu, X., Bu, X. et al., IL-21 induces an imbalance of Th17/Treg cells in moderate-to-severe plaque psoriasis patients. Front. Immunol. 2019. 10: 1865.
Niu, J., Zhai, Z., Hao, F., Zhang, Y., Song, Z. and Zhong, H., Dissection of a circulating CD3(+) CD20(+) T cell subpopulation in patients with psoriasis. Clin. Exp. Immunol. 2018. 192: 206-212.
Mariette, X. and Criswell, L. A., Primary Sjogren's syndrome. N. Engl. J. Med. 2018. 378: 931-939.
Brito-Zeron, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Sivils, K. et al., Sjogren syndrome. Nat. Rev. Dis. Primers 2016. 2: 16047.
De Paiva, C. S., Hwang, C. S., Pitcher J. D., 3rd, Pangelinan, S. B., Rahimy, E., Chen, W., Yoon, K.-C. et al., Age-related T-cell cytokine profile parallels corneal disease severity in Sjogren's syndrome-like keratoconjunctivitis sicca in CD25KO mice. Rheumatology (Oxford) 2010. 49: 246-258.
McGuire, H. M., Vogelzang, A., Ma, C. S., Hughes, W. E., Silveira, P. A., Tangye, S. G., Christ, D. et al., A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity. Immunity 2011. 34: 602-615.
Liu, H., Liu, G., Gong, L., Zhang, Y. and Jiang, G., Local suppression of IL-21 in submandibular glands retards the development of Sjogren's syndrome in non-obese diabetic mice. J. Oral Pathol. Med. 2012. 41: 728-735.
Maiti, A. K., Kim-Howard, X., Viswanathan, P., Guillen, L., Rojas-Villarraga, A., Deshmukh, H., Direskeneli, H. et al., Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. Arthritis Rheum. 2010. 62: 323-329.
Kang, K. Y., Kim, H. O., Kwok, S. K., Ju, J. H., Park, K. S., Sun, D. I., Jhun, J. et al., Impact of interleukin-21 in the pathogenesis of primary Sjogren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res. Ther. 2011. 13: R179.
Loureiro-Amigo, J., Franco-Jarava, C., Perurena-Prieto, J., Palacio, C., Martinez-Valle, F. and Solans-Laque, R., Serum CXCL13, BAFF, IL-21 and IL-22 levels are related to disease activity and lymphocyte profile in primary Sjogren's syndrome. Clin. Exp. Rheumatol. 2021. 133: 131-139.
Kwok, S. K., Lee, J., Yu, D., Kang, K. Y., Cho, M. L., Kim, H. R., Ju, J. H. et al. A pathogenetic role for IL-21 in primary Sjogren syndrome. Nat. Rev. Rheumatol. 2015. 11: 368-374.
Szabo, K., Jambor, I., Szanto, A., Horvath, I. F., Tarr, T., Nakken, B., Szodoray, P. et al., The imbalance of circulating follicular T helper cell subsets in primary Sjogren's syndrome associates with serological alterations and abnormal B-cell distribution. Front. Immunol. 2021. 12: 639975.
Allanore, Y., Simms, R., Distler, O., Trojanowska, M., Pope, J., Denton, C. P., Varga, J. Systemic sclerosis. Nat. Rev. Dis. Primers 2015. 1: 15002.
Wynn, T. A., Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008. 214: 199-210.
Diaz-Gallo, L. M., Simeon, C. P., Broen, J. C., Ortego-Centeno, N., Beretta, L., Vonk, M. C., Carreira, P. E et al., Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann. Rheum. Dis. 2013. 72: 1233-1238.
Lei, L., He, Z. Y., Zhao, C., Sun, X. J. and Zhong, X. N., Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis. Int. J. Rheum. Dis. 2016. 19: 392-404.
Taylor, D. K., Mittereder, N., Kuta, E., Delaney, T., Burwell, T., Dacosta, K., Zhao, W. et al., T follicular helper-like cells contribute to skin fibrosis. Sci. Transl. Med. 2018. 10: eaaf5307.
Ly, N. T. M., Ueda-Hayakawa, I., Nguyen, C. T. H., Huynh, T. N. M., Kishimoto, I., Fujimoto, M., Okamoto, H. et al., Imbalance toward TFH 1 cells playing a role in aberrant B cell differentiation in systemic sclerosis. Rheumatology (Oxford) 2021. 60: 1553-1562.
Distler, J. H., Jungel, A., Kowal-Bielecka, O., Michel, B. A., Gay, R. E., Sprott, H., Matucci-Cerinic, M. et al., Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 2005. 52: 856-864.
Bain, K. A., McDonald, E., Moffat, F., Tutino, M., Castelino, M., Barton, A., Cavanagh, J. et al., Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br. J. Dermatol. 2020. 182: 130-137.
Atwa, M. A., Youssef, N. and Bayoumy, N. M., T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-alpha) in patients with alopecia areata: association with clinical type and severity. Int. J. Dermatol. 2016. 55: 666-672.
Zhou, L., Shi, Y. L., Li, K., Hamzavi, I., Gao, T. W., Huggins, R. H., Lim, H. et al., Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res. 2015. 28: 324-329.
Shi, F. and Erf, G. F., IFN-gamma, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens. J. Invest. Dermatol. 2012. 132(Pt 1): 642-649.
Li, Q., Liu, Z., Dang, E., Jin, L., He, Z., Yang, L., Shi, X. et al., Follicular helper T Cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid. PLoS One 2013. 8: e68145.
Geri, G., Terrier, B., Rosenzwajg, M., Wechsler, B., Touzot, M., Seilhean, D., Tran, T. et al., Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J. Allergy Clin. Immunol. 2011. 128: 655-664.
Liu, T., Hou, Y., Dai, T. J. and Yan, C. Z., Upregulation of interleukin 21 and interleukin 21 receptor in patients with dermatomyositis and polymyositis. Chin. Med. J. (Engl.) 2017. 130: 2101-2106.
Welsch, K., Holstein, J., Laurence, A. and Ghoreschi, K., Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur. J. Immunol. 2017. 47: 1096-1107.
Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. W. et al., Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 2011. 186: 4234-4243.
Reighard, S. D., Cranert, S. A., Rangel, K. M., Ali, A., Gyurova, I. E., de la Cruz-Lynch, A. T., Tuazon, J. A. et al., Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells. Cell Rep. Med. 2020. 1: 100003.
Xue, L., Hickling, T., Song, R., Nowak, J. and Rup, B., Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody. Clin. Exp. Immunol. 2016. 183: 102-113.
Hua, F., Comer, G. M., Stockert, L., Jin, B., Nowak, J., Pleasic-Williams, S., Wunderlich, D. et al., Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J. Clin. Pharmacol. 2014. 54: 14-22.
Holland, S. M., DeLeo, F. R., Elloumi, H. Z., Hsu, A. P., Uzel, G., Brodsky, N., Freeman, A. F. et al., STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 2007. 357: 1608-1619.
Frey-Jakobs, S., Hartberger, J. M., Fliegauf, M., Bossen, C., Wehmeyer, M. L., Neubauer, J. C., Bulashevska, A. et al., ZNF341 controls STAT3 expression and thereby immunocompetence. Sci Immunol 2018. 3: eaaat4941.
Beziat, V., Li, J., Lin, J. X., Ma, C. S., Li, P., Bousfiha, A., Pellier, I. et al., A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity. Sci Immunol 2018. 3: eaat4956.
Notarangelo, L. D., Mella, P., Jones, A., de Saint Basile, G., Savoldi, G., Cranston, T., Vihinen, M. et al., Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum. Mutat. 2001. 18: 255-263.
Macchi, P., Villa, A., Giliani, S., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G. et al., Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995. 377: 65-68.
Puck, J. M., Pepper, A. E., Henthorn, P. S., Candotti, F., Isakov, J., Whitwam, T., Conley, M. E. et al., Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood 1997. 89: 1968-1977.